Literature DB >> 7834641

In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma.

C Gaudin1, P Y Dietrich, S Robache, M Guillard, B Escudier, M J Lacombe, A Kumar, F Triebel, A Caignard.   

Abstract

Renal cell carcinoma (RCC) is one human tumor to which the immune response may control the growth of tumor cells. These tumors are infiltrated by a large mononuclear infiltrate mainly composed of T lymphocytes. To characterize the lymphocytes infiltrating RCC, we analyzed the molecular structure of the T cell receptor (TCR) alpha and beta chains in tumor and paired peripheral blood lymphocytes from a series of 6 untreated patients. We first determined V alpha and V beta gene segment usage by PCR using a panel of V specific oligonucleotide primers (V alpha 1-w29 and V beta 1-w24). A highly diverse usage of TCR V alpha and V beta gene usage was observed in 5 of 6 tumors. In addition, the few tumor overexpressed V beta specificities detected by reverse transcription-PCR were shown to contain minor T cell expansions. Strikingly, 1 of the 6 tumor studied displayed a skewed TCR repertoire with V beta 4 transcript representing 25% of the TCR signals. Clonality of the tumor overexpressed V beta transcripts was analyzed by CDR3 size distribution analysis. In the particular tumor displaying a biased repertoire large expansions of T cell subpopulations were detected (particularly in V beta 4) specifically at the tumor site. Such T cells may be expanded locally in response to tumor antigens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7834641

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Cellular immunity in osteoarthritis: novel concepts for an old disease.

Authors:  S N Liossis; G C Tsokos
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

3.  Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast.

Authors:  Hajime Kuroda; Jun-ichi Tamaru; Goi Sakamoto; Kiyoshi Ohnisi; Shinji Itoyama
Journal:  Virchows Arch       Date:  2004-11-30       Impact factor: 4.064

4.  Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients.

Authors:  Sebastian Ochsenreither; Alberto Fusi; Susanne Wojtke; Antonia Busse; Natascha C Nüssler; Eckhard Thiel; Ulrich Keilholz; Dirk Nagorsen
Journal:  J Transl Med       Date:  2010-04-12       Impact factor: 5.531

Review 5.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

Review 6.  Oligoclonal T cells in human cancer.

Authors:  E Halapi
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

7.  Clonal T cell expansion induced by interleukin 2 therapy in blood and tumors.

Authors:  A Kumar; F Farace; C Gaudin; F Triebel
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

Review 8.  Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.

Authors:  Aurélie Durgeau; Yasemin Virk; Stéphanie Corgnac; Fathia Mami-Chouaib
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

9.  A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.

Authors:  Osama E Rahma; Ed Ashtar; Ramy Ibrahim; Antoun Toubaji; Barry Gause; Vincent E Herrin; W Marston Linehan; Seth M Steinberg; Frank Grollman; George Grimes; Sarah A Bernstein; Jay A Berzofsky; Samir N Khleif
Journal:  J Transl Med       Date:  2010-01-28       Impact factor: 5.531

10.  A study exploring critical pathways in clear cell renal cell carcinoma.

Authors:  Zisan Zeng; Tengcheng Que; Jiange Zhang; Yanling Hu
Journal:  Exp Ther Med       Date:  2013-11-07       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.